Laurus labs share

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Sales + 829 970 1,127 1,272 1,399 1,221 1,176 933 1,378 1,495 1,498 1,501 1,279 Expenses + 636 706 759 858 936 858 842 717 1,005 1,077 1,072 1,116 1,027 Operating Profit 193 265 368 415 462 363 334 215 373 418 426 385 252 OPM % 23% 27% 33% 33% 33% 30% 28% 23% 27% 28% 28% 26% 20% Other Income + 2 6 7 9 6 8 4 7 2 3 4 3 6 Interest 20 15 13 17 21 25 21 21 29 28 38 39 41 Depreciation 45 48 49 49 51 55 59 60 61 66 76 78 81 Profit before tax 129 209 312 357 396 290 258 142 285 328 317 270 137 Tax % 13% 24% 24% 25% 26% 23% 24% 23% 22% 29% 28% 26% 25% Net Profit + 113 159 238 267 293 222 198 109 221 232 227 199 102 EPS in Rs 2.10 2.97 4.43 4.98 5.46 4.14 3.68 2.03 4.12 4.31 4.23 3.70 1.90 Raw PDF Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sales + 451 719 1,160 1,326 1,775 1,892 2,027 2,236 2,797 4,769 4,707 5,773 Expenses + 373 573 951 1,121 1,402 1,478 1,618 1,884 2,226 3,258 3,421 4,292 Operating Profit 78 145 209 205 372 414 409 352 571 1,511 1,286 1,482 OPM % 17% 20% 18% 15% 21% 22% 20% 16% 20% 32% 27% 26% Other Income + 1 5 9 34 4 32 28 15 5 26 20 16 Interest 40 41 64 106 111 97 75 86 88 66 96 146 Depreciation 18 23 33 61 86 104 121 161 184 197 235 301 Profit before tax 22 86 121 72 180 245 241 121 304 1,275 975 1,051 Tax % 0% -2% 20% -2% 19% 18% 28% 22% 12% 25% 23% 28% Net Profit + 22 88 97 74 145...

Laurus Labs Limited Quick Overview Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company is a manufacturer of active pharmaceutical ingredients (API) for antiretroviral (ARV), oncology, cardiovascular, antidiabetics, anti-asthma and gastroenterology. It also develops and manufactures oral solid formulations, which provide contract research and manufacturing services (CRAMS) to other global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals. The Company operates through four business units covering a range of therapeutic applications, including Generics API, which is engaged in the development, manufacture and sale of APIs and advanced intermediates; Generics Finished Dosage Form (FDF), which is engaged in the development and manufacture of oral solid formulations; Synthesis, which is a key starting materials, intermediates and APIs for New Chemical Entities (NCEs), and Bio, which is engaged in the recombinant products.

• Adani Enterp. 2650.85 ↑ 324.75 (13.96%) • Adani Ports 737.90 ↑ 8.20 (1.12%) • Apollo Hospitals 4559.25 ↓ -46.05 (-1.00%) • Asian Paints 3120.50 ↑ 35.60 (1.15%) • Axis Bank 917.70 ↑ 0.15 (0.02%) • B P C L 366.95 ↑ 5.35 (1.48%) • Bajaj Auto 4499.70 ↓ -23.55 (-0.52%) • Bajaj Finance 6794.80 ↑ 1.75 (0.03%) • Bajaj Finserv 1440.00 ↑ 27.00 (1.91%) • Bharti Airtel 800.55 ↓ -1.30 (-0.16%) • Britannia Inds. 4522.50 ↑ 23.55 (0.52%) • Cipla 930.05 ↑ 5.10 (0.55%) • Coal India 239.25 ↑ 0.55 (0.23%) • Divi's Lab. 3386.95 ↑ 121.95 (3.74%) • Dr Reddy's Labs 4462.90 ↑ 5.25 (0.12%) • Eicher Motors 3602.55 ↑ 57.10 (1.61%) • Grasim Inds 1699.50 ↓ -18.85 (-1.10%) • H D F C 2710.00 ↑ 5.25 (0.19%) • HCL Technologies 1107.30 ↓ -12.55 (-1.12%) • HDFC Bank 1638.40 ↓ -2.65 (-0.16%) • HDFC Life Insur. 563.15 ↓ -3.85 (-0.68%) • Hero Motocorp 2702.75 ↑ 10.60 (0.39%) • Hind. Unilever 2628.05 ↓ -10.05 (-0.38%) • Hindalco Inds. 410.95 ↑ 3.25 (0.80%) • ICICI Bank 954.70 ↑ 4.35 (0.46%) • IndusInd Bank 1260.65 ↑ 14.50 (1.16%) • Infosys 1301.50 ↑ 8.70 (0.67%) • ITC 429.60 ↑ 4.85 (1.14%) • JSW Steel 704.05 ↓ -0.55 (-0.08%) • Kotak Mah. Bank 1921.30 ↓ -18.90 (-0.97%) • Larsen & Toubro 2199.45 ↓ -17.15 (-0.77%) • M & M 1268.70 ↑ 3.15 (0.25%) • Maruti Suzuki 9206.95 ↑ 50.30 (0.55%) • Nestle India 21412.15 ↓ -82.65 (-0.38%) • NTPC 174.30 ↑ 0.20 (0.11%) • O N G C 164.90 ↓ -0.70 (-0.42%) • Power Grid Corpn 234.10 ↓ -0.25 (-0.11%) • Reliance Industr 2456.10 ↑ 1.10 (0.04%) • SBI Life Insuran 1166.25 ↑ 15.45 (1.34%) ...

Possible buy opportunity coming up in Lauruslabs counter (Breakout not yet confirmed, but looks promising) Cup & Handle pattern formed. Reversal confirmed from long term down trend from a base of 290. I also think that the consolidation flag at the resistance line of C&H pattern, today' volume incr Possible buy opportunity coming up in Lauruslabs counter (Breakout not yet confirmed, but looks promising) Cup & Handle pattern formed. Reversal confirmed from long term down trend from a base of 290. I also think that the consolidation flag at the resistance line of C&H pattern, today' volume incr A clear cut confirmed breakout of rounding bottom pattern formed on daily hart of Laurus labs at 340 level. Can go up to 400 in very near term. Can go long with strict so of 335. A clear cut confirmed breakout of rounding bottom pattern formed on daily hart of Laurus labs at 340 level. Can go up to 400 in very near term. Can go long with strict so of 335. Laurus lab has fallen much and formed bullish pin bar on weekly chart. It likely to get pullback up to the previous demand zone (430), however it might touch 20 EMA and and halt for few sessions before going up. Better entry would be@ 315 ~320 , and stop loss must be 270 on daily closing basis. Laurus lab has fallen much and formed bullish pin bar on weekly chart. It likely to get pullback up to the previous demand zone (430), however it might touch 20 EMA and and halt for few sessions before going up. Better entry would be@ 315 ~320...

We use cookies and browser capability checks to help us deliver our online services, including to learn if you enabled Flash for video or ad blocking. By using our website or by closing this message box, you agree to our use of browser capability checks, and to our use of cookies as described in our Valuation P/E Ratio (TTM) - P/E Ratio (including extraordinary items) - Price to Sales Ratio - Price to Book Ratio - Price to Cash Flow Ratio - Enterprise Value to EBITDA 13.41 Enterprise Value to Sales 3.53 Total Debt to Enterprise Value - Total Debt to EBITDA 1.27 EPS (recurring) - EPS (basic) 14.69 EPS (diluted) 14.64 Jan 0001 5-quarter trend Cash & Short-Term Investment 484.60 M Total Debt 20.15 B Total Liabilities 36.12 B Total Shareholder's Equity 40.38 B Book Value Per Share - - 1 5-year trend Cash & Short-Term Investment 484.60 M Total Debt 20.15 B Total Liabilities 36.12 B Total Shareholder's Equity 40.38 B Book Value Per Share - -

Summary Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020 Sep 2020 Jun 2020 27.2% 27.2% 27.3% 27.3% 27.3% 27.3% 27.3% 27.3% 27.5% 28.7% 32.1% 32.1% Holding 27.2% 27.2% 27.3% 27.3% 27.3% 27.3% 27.3% 27.3% 27.5% 28.7% 32.1% 32.1% Pledged 0.04% 0.04% 0.04% 0.0% 0.0% 0.0% 0.0% 0.0% 1.15% 15.78% 16.42% 31.56% Locked 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 22.4% 21.9% 22.7% 22.0% 22.4% 22.1% 22.8% 21.5% 20.7% 19.9% 20.7% 16.1% 9.7% 9.5% 9.3% 9.1% 8.0% 6.9% 4.9% 4.2% 3.6% 4.1% 6.3% 8.8% 40.6% 41.4% 40.7% 41.6% 42.4% 43.8% 45.1% 47.0% 48.3% 47.3% 40.8% 43.0% 0% 0.0% 0% 0% 0% 0% 0% 0% 0% 0.0% 0.0% 0% Name Holding Mar 2023 No of holders Indian/Foreign Pledged History % shares % shares 2.91 15,686,856 13 Indian 0.38 60,000 2.50 13,450,145 - Indian 0.00 0 0.19 1,000,000 - Indian 0.00 0 0.04 225,000 - Indian 0.00 0 0.04 201,397 - Indian 0.00 0 0.03 147,500 - Indian 40.68 60,000 0.03 170,000 - Indian 0.00 0 0.02 100,000 - Indian 0.00 0 0.02 100,000 - Indian 0.00 0 0.02 100,000 - Indian 0.00 0 0.02 119,675 - Indian 0.00 0 0.01 42,000 - Indian 0.00 0 0.00 20,699 - Indian 0.00 0 0.00 10,440 - Indian 0.00 0 24.29 130,831,740 2 Indian 0.00 0 23.04 124,126,740 - Indian 0.00 0 1.24 6,705,000 - Indian 0.00 0 Name Holding Mar 2023 No of holders History % shares 10.38 55,898,844 101 1.33 7,151,700 - Individual share capital upto Rs. 2 Lacs 18.11 97,570,994 404,910 1.46 7,839,747 4,929 0.69 3,719,521 - 0.51 2,722,007 - 0.26 1,398,219 - 8....

Laurus Labs' EBITDA improved to Rs 404 crore in Q3FY23, recording 39% YoY growth. The EBITDA margin stood at 26.1% in the quarter. Its EPS for the period stood at Rs 3.7 per share. “Our Q3 and 9M of 2023 results reflect sustained business momentum across our key growth drivers, which is visible in our commercial execution within CDMO, and Non-ARVs generic portfolio. Growth is also supported by anticipated recovery in the ARV FDF segment, which is likely to continue despite pricing challenges. We also made additional advancements in our R&D initiatives and brought new capacities online," said Satyanarayana Chava, Founder & CEO of Laurus Labs. • 819.90 03:59 PM | 13 Jun 2023 19.15 (2.39%) 981.50 03:57 PM | 13 Jun 2023 21.55 (2.24%) 3,262.85 03:59 PM | 13 Jun 2023 68.10 (2.13%) 2,912.50 03:57 PM | 13 Jun 2023 59.90 (2.10%) • 1,855.95 03:59 PM | 13 Jun 2023 -23.50 (-1.25%) 2,462.55 03:59 PM | 13 Jun 2023 -22.25 (-0.90%) 1,131.30 03:59 PM | 13 Jun 2023 -8.35 (-0.73%) 1,373.15 03:59 PM | 13 Jun 2023 -8.25 (-0.60%)

15 Jun 366.75 (2.16%) 14 Jun 359.00 (-0.31%) 13 Jun 360.10 (4.86%) 12 Jun 343.40 (0.85%) 09 Jun 340.50 (-1.92%) 08 Jun 347.15 (-0.49%) 07 Jun 348.85 (1.99%) 06 Jun 342.05 (0.12%) 05 Jun 341.65 (-1.27%) 02 Jun 346.05 (1.63%) 01 Jun 340.50 (2.96%) 31 May 330.70 (-0.32%) 30 May 331.75 (-0.87%) 29 May 334.65 (-0.06%) 26 May 334.85 (0.43%) 25 May 333.40 (-0.42%) 24 May 334.80 (6.47%) 23 May 314.45 (0.75%) 22 May 312.10 (-0.10%) 19 May 312.40 (0.64%) 18 May 310.40 (-0.46%) Intraday Support and Resistance (Based on Pivot Points) | Updated On Jun 15, 2023 04:00 PM For Next Trading Session Pivots Classic Fibonacci Camarilla Woodie DM R3 383.4 376.35 370.01 - - R2 376.35 371.82 368.92 376.91 - R1 371.55 369.03 367.84 372.67 373.95 P 364.5 364.5 364.5 365.06 365.7 S1 359.7 359.97 365.66 360.82 362.1 S2 352.65 357.18 364.58 353.21 - S3 347.85 352.65 363.49 - - Laurus Labs Ltd Profit & Loss Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 INCOME 756.76 1238.83 1444.84 1804.07 1959.95 2080.79 2281.2 3021.24 5092.49 4947.21 PROFIT 88.45 96.85 73.5 144.88 200.07 173.51 95.61 267.72 956.74 750.94 EPS 57.88 63.21 47.39 91.74 3.78 3.27 1.78 5 17.82 13.96 Mar 2022 Mar 2021 Mar 2020 Mar 2019 Mar 2018 Mar 2017 Mar 2016 Mar 2015 Mar 2014 SOURCES OF FUNDS : Share Capital 107.47 107.32 106.91 106.44 106.03 105.76 82.38 82.13 77.84 Reserves Total 3,243.72 2,490.23 1,658.23 1,446.6 1,370.75 1,224.69 774.42 639.98 280.58 Equity Application Money 0 0 4.63 5.37 ...